AU2002328388B2 - Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor - Google Patents
Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor Download PDFInfo
- Publication number
- AU2002328388B2 AU2002328388B2 AU2002328388A AU2002328388A AU2002328388B2 AU 2002328388 B2 AU2002328388 B2 AU 2002328388B2 AU 2002328388 A AU2002328388 A AU 2002328388A AU 2002328388 A AU2002328388 A AU 2002328388A AU 2002328388 B2 AU2002328388 B2 AU 2002328388B2
- Authority
- AU
- Australia
- Prior art keywords
- peg
- crosslinked
- linkages
- group
- crosslinked polymeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229920001223 polyethylene glycol Polymers 0.000 title claims description 203
- -1 poly(ethylene glycol) Polymers 0.000 title claims description 55
- 239000000017 hydrogel Substances 0.000 title claims description 53
- 239000002243 precursor Substances 0.000 title description 7
- 150000002148 esters Chemical class 0.000 claims description 44
- 229920000642 polymer Polymers 0.000 claims description 38
- 150000001412 amines Chemical class 0.000 claims description 36
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
- 239000011159 matrix material Substances 0.000 claims description 21
- 230000007062 hydrolysis Effects 0.000 claims description 20
- 238000006460 hydrolysis reaction Methods 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 claims description 12
- 150000002466 imines Chemical class 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 12
- 238000012377 drug delivery Methods 0.000 claims description 10
- 239000012948 isocyanate Substances 0.000 claims description 10
- 150000002513 isocyanates Chemical class 0.000 claims description 10
- 150000002905 orthoesters Chemical class 0.000 claims description 10
- 150000001408 amides Chemical class 0.000 claims description 9
- 150000003014 phosphoric acid esters Chemical class 0.000 claims description 8
- 229910019142 PO4 Inorganic materials 0.000 claims description 7
- 150000007857 hydrazones Chemical class 0.000 claims description 7
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 claims description 7
- 239000010452 phosphate Substances 0.000 claims description 7
- 229940124530 sulfonamide Drugs 0.000 claims description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 5
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 5
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- 150000003456 sulfonamides Chemical class 0.000 claims description 5
- WMYINDVYGQKYMI-UHFFFAOYSA-N 2-[2,2-bis(hydroxymethyl)butoxymethyl]-2-ethylpropane-1,3-diol Chemical compound CCC(CO)(CO)COCC(CC)(CO)CO WMYINDVYGQKYMI-UHFFFAOYSA-N 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 229940088623 biologically active substance Drugs 0.000 claims 4
- 235000013877 carbamide Nutrition 0.000 claims 4
- 150000003672 ureas Chemical class 0.000 claims 4
- 150000003673 urethanes Chemical class 0.000 claims 4
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 claims 2
- 150000002118 epoxides Chemical class 0.000 claims 2
- 150000002430 hydrocarbons Chemical group 0.000 claims 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims 1
- 235000009685 Crataegus X maligna Nutrition 0.000 claims 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims 1
- 235000009486 Crataegus bullatus Nutrition 0.000 claims 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims 1
- 235000009682 Crataegus limnophila Nutrition 0.000 claims 1
- 235000004423 Crataegus monogyna Nutrition 0.000 claims 1
- 240000000171 Crataegus monogyna Species 0.000 claims 1
- 235000002313 Crataegus paludosa Nutrition 0.000 claims 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 150000004675 formic acid derivatives Chemical class 0.000 claims 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000499 gel Substances 0.000 description 32
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- 238000006243 chemical reaction Methods 0.000 description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 239000002253 acid Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 229940079593 drug Drugs 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000000047 product Substances 0.000 description 14
- 230000015556 catabolic process Effects 0.000 description 11
- PVVTWNMXEHROIA-UHFFFAOYSA-N 2-(3-hydroxypropyl)-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(CCCO)=NC(=O)C2=C1 PVVTWNMXEHROIA-UHFFFAOYSA-N 0.000 description 10
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 150000001299 aldehydes Chemical class 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- 125000003277 amino group Chemical group 0.000 description 7
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 7
- 230000003301 hydrolyzing effect Effects 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000006116 polymerization reaction Methods 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 241001415846 Procellariidae Species 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 5
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 5
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 5
- 235000019260 propionic acid Nutrition 0.000 description 5
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 150000002924 oxiranes Chemical class 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 240000006670 Chlorogalum pomeridianum Species 0.000 description 3
- 235000007836 Chlorogalum pomeridianum Nutrition 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000009895 amole Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000008366 buffered solution Substances 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 229920006037 cross link polymer Polymers 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
- 238000002390 rotary evaporation Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate group Chemical group C(C=C)(=O)[O-] NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- 150000001263 acyl chlorides Chemical class 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 229920001427 mPEG Polymers 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229940094938 stannous 2-ethylhexanoate Drugs 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 125000001273 sulfonato group Chemical class [O-]S(*)(=O)=O 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 229920001734 PEG propionaldehyde Polymers 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- ACBQROXDOHKANW-UHFFFAOYSA-N bis(4-nitrophenyl) carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 ACBQROXDOHKANW-UHFFFAOYSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000009616 inductively coupled plasma Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Description
P/00/011 2815/91 Regulation 3.2(2)
AUSTRALIA
Patents Act 1990 COMPLETE SPECIFICATION STANDARD PATENT Application Number: Lodged: Invention Title: DEGRADABLE POLY(ETHYLENE GLYCOL) HYDROGELS WITH CONTROLLED HALF-LIFE AND PRECURSORS THEREFOR The following statement is a full description of this invention, including the best method of performing it known to us DEGRADABLE POLY(ETHYLENE GLYCOL) HYDROGELS WITH CONTROLLED HALF-LIFE AND PRECURSORS THEREFOR FIELD OF THE INVENTION This invention relates to poly(ethylene glycol) hydrogels, precursors therefor, methods for making the precursors and hydrogels, and the use of the precursors and hydrogels.
BACKGROUND OF THE INVENTION In its most common form, poly(ethylene glycol) (PEG) is a linear polymer terminated at each end with hydroxyl groups:
HO-CH
2 CH20-(CH 2
CH
2 O) ,-CH 2
CH
2
-OH
This polymer can be represented in brief form as HO-PEG-OH where it is understood that -PEG- represents the following structural unit:
-CH
2
CH
2 0-(CH 2
CH
2 0)n-CH 2
CH
2 n typically ranges from approximately 10 to 2000.
PEG is of great utility in biotechnology and is useful in a variety of applications for drug delivery and modification of surfaces to promote nonfouling characteristics, including as hydrogels and for covalent attachment to various drugs and surfaces. PEG is not toxic, does not tend to promote an immune response, and is soluble in water and in many organic solvents.
The PEG polymer can be covalently attached to insoluble molecules to make the resulting PEG-molecule conjugate soluble. For example, Greenwald, Pendri and Bolikal in J. Org. Chem., 60, 331-336 (1995) recite that the water-insoluble drug taxol, when coupled to PEG, becomes water soluble.
Davis et al. in U.S. patent 4,179,337 recite that proteins coupled to PEG have an enhanced blood circulation lifetime because of a reduced rate of kidney clearance and reduced immunogenicity. The lack of toxicity of the polymer and its rate of clearance from the body are important considerations in pharmaceutical applications. Pharmaceutical applications and many leading references are described in the book by Harris M. Harris, Ed., "Biomedical and Biotechnical Applications of Polyethylene Glycol Chemistry," Plenum, New York, 1992).
PEG is commonly used as methoxy-PEG-OH, or mPEG in brief, in which one terminus is the relatively inert methoxy group, while the other terminus is an hydroxyl group that is subject to ready chemical modification.
2
CH
2 0)n-CH 2
CH
2 -OH mPEG PEG is also commonly used in branched forms that can be prepared by addition of ethylene oxide to various polyols, including glycerol, pentaerythritol and sorbitol. For example, the four-armed branched PEG prepared from pentaerythritol is shown below:
C(CH
2
-OH)
4 nC 2
H
4 O C[CH 2 0-(CHCH20) n-CH 2
CH
2
-OH],
The branched PEGs can be represented in general form as R(-PEG-OH)n in which R represents the central core molecule, which can include glycerol or pentaerythritol, and n represents the number of arms.
It is necessary to use an "activated derivative" of PEG to couple PEG to a molecule. The hydroxyl group located at the PEG terminus or other group subject to ready chemical modification is activated by modifying or replacing the group with a functional group suitable for reacting with a group on another molecule, including proteins, surfaces, enzymes, and others. For example, the succinimidyl "active ester" of carboxymethylated PEG forms covalent bonds with amino groups on proteins as described by K. Iwasaki and Y. Iwashita in U.S. Patent 4,670,417.
The synthesis described in U.S. Patent No. 4,670,417 is illustrated below with the active ester reacting with amino groups of a protein in which the succinimidyl group is represented as NHS and the protein is represented as PRO-NH 2
PEG-O-CH
2 -CO2-NHS PRO-NH
PEG-O-CH
2
-CO
2
-NH-PRO
Succinimidyl "active esters", such as PEG-O-CH 2 -CO2-NHS, are commonly used forms of activated carboxylic acid PEGs, and they are prepared by reacting carboxylic acid PEGs with N-hydroxylsuccinimide.
Problems have arisen in the art. Some of the functional groups that have been used to activate PEG can result in toxic or otherwise undesirable residues when used for in vivo drug delivery. Some of the linkages that have been devised to attach functional groups to PEG can result in an undesirable immune response. Some of the functional groups do not have sufficient or otherwise appropriate selectivity for reacting with particular groups on proteins and can tend to deactivate the proteins.
PEG hydrogels, which are water-swollen gels, have been used for wound covering and drug delivery. PEG hydrogels are prepared by incorporating the soluble, hydrophilic polymer into a chemically crosslinked network or matrix so that addition of water produces an insoluble, swollen gel. Substances useful as drugs typically are not covalently attached to the PEG hydrogel for in vivo delivery. Instead, the substances are trapped within the crosslinked matrix and pass through the interstices in the matrix. The insoluble matrix can remain in the body indefinitely and control of the release of the drug typically can be somewhat imprecise.
One approach to preparation of these hydrogels is described by Embrey and Grant in U.S. Patent No. 4,894,238. The ends of the linear polymer are connected by various strong, nondegradable chemical linkages. For example, linear PEG is incorporated into a crosslinked network by reacting with a triol and a diisocyanate to form hydrolytically stable urethane linkages that are nondegradable in water.
A related approach for preparation of PEG hydrogels has been described by Gayet and Fortier in Controlled Release, 38, 177-184 (1996) in which linear PEG was activated as the p-nitrophenylcarbonate and crosslinked by reaction with a protein, bovine serum albumin. The linkages formed are hydrolytically stable urethane groups and the hydrogels are nondegradable in water.
In another approach, described by N.S. Chu in U.S. Patent 3,963,805, nondegradable PEG networks have been prepared by random entanglement of PEG chains with other polymers formed by use of free radical initiators mixed with multifunctional monomers. P.A. King described nondegradable PEG hydrogels in U.S. Patent 3,149,006 that have been prepared by radiation-induced crosslinking of high molecular weight PEG.
Nagaoka et al. in U.S. Patent 4,424,311 have prepared PEG hydrogels by copolymerization of PEG methacrylate with other comonomers such as methyl methacrylate. Substantial non-PEG polymeric elements are introduced by this method. Vinyl polymerization produces a polyethylene backbone with PEG attached.
The methyl methacrylate comonomer is added to give the gel additional physical strength.
European Patent Application EP 0 593 284 discloses the synthesis and use of poly(ethylene glycols) with photochemically or thermochemically activated cross-linking groups at the chain ends. Exposure to light or heat, respectively, causes these cross-linking groups to react randomly with various bonds in the polymer backbone by alkylation or acylation. A biodegradable peptide can be included in the polymer. These peptides are degradable by enzyme catalyzed processes.
European Patent Applications EP 0 794 211 and EP 0 771 832 relate to copolymers and blends of polyesters with other components where the polymers are formed by high temperature melt polymerization. The esters are acetate esters that include the moiety -O-CH 2
CO
2 These esters would be expected to hydrolyze to produce ethylene glycol, which is a toxic compound.
-4a- Sawhney, Pathak and Hubbell in Macromolecules, 26, 581 (1993) describe the preparation of block copolymers of polyglycolide or polylactide and PEG that are terminated with acrylate groups, as shown below.
CH2=CH-CO-(O-CH2-CO)n-O-PEG-O-(CO-CH2-O)n-CO-CHCH2 In the above formula, the glycolide blocks are the -O-CH 2 -CO- units; addition of a methyl group to the methylene gives a lactide block; n can be multiples of 2. Vinyl polymerization of the acrylate groups produces an O insoluble, crosslinked gel with a polyethylene backbone.
c N Substantial non-PEG elements are introduced into the hydrogel. The polylactide or polyglycolide segments of the polymer backbone shown above, which are ester groups, are susceptible to slow hydrolytic breakdown, with the result that the crosslinked gel undergoes slow degradation and dissolution.
Non-PEG elements tend to introduce complexity into the hydrogel and o00 00oo degradation and dissolution of the matrix can result in undesirable or toxic 00 components being released into the blood stream when the hydrogels are used in en vivo for drug delivery.
o 10 It would be desirable to provide alternative PEG hydrogels that are suitable CN for drug delivery and that have unique properties that could enhance drug delivery systems.
SUMMARY OF THE INVENTION According to the present invention there is provided a crosslinked polymeric structure comprising poly(ethylenglycol) (PEG) polymers in the absence of non-PEG polymer, said PEG polymers crosslinked through groups which are reactive toward each other, and said PEG polymers having a central branching moiety and at least some hydrolytically unstable linkages between said PEG polymers said hydrolytically unstable linkages being selected from the group consisting of carboxylate esters and phosphate esters, imines, hydrazones, acetals and orthoesters, wherein the carboxylate ester is a monomeric ester according to the formula -O-(CH2)r-C02-, wherein r is from 1 to The invention provides chemically crosslinked degradable PEG hydrogels capable of controlled degradability and methods for making these PEG hydrogels in the absence of non-PEG elements. Weak chemical linkages are introduced into the hydrogel that provide for hydrolytic breakdown of the crosslinks and release of drug molecules that can be trapped within the matrix. The gels break down to substantially nontoxic PEG fragments that typically are cleared from the body. Variation of the atoms near the hydrolytically unstable linkages can provide precise control of hydrolytic breakdown rate and drug release. The hydrolytically unstable linkages include carboxylate ester, phosphate ester, acetals, imines and orthoesters. These weak links are formed by reaction of two PEGs having different terminal groups as illustrated below: -PEG-Z Y-PEG-
-PEG-W-PEG-
In the above illustration, represents the hydrolytically unstable weak link. Z- and Y- represent groups located at the terminus of the PEG molecule that are capable of reacting with each other to form weak links For example, the following pairs of Z and Y groups can be used to form some of the W groups described above:
-PEG-CO
2 H HO-PEG-
-PEG-CO
2 -PEG- ester -PEG-OP0 3
H
2 HO-PEG
-PEG-OPO
3 (H)-PEG- phosphate ester -PEG-CHO
(HO-PEG)
2 -PEG-CH(O-PEG) 2 acetal -PEG-CHO
NH
2 -PEG- -PEG-CH=N-PEG- imine The PEG hydrogels of the invention can be made by either a two-step or a one-step method. In the one-step approach, two different PEGs with the appropriate terminal groups are reacted in a single step. A specific example of the one-step approach according to the invention is shown in the following equation for coupling of linear PEG acids with a three-armed PEG terminated with hydroxyl groups. Weak ester linkages are formed.
HO
2
C-(CH
2 )n-O-PEG-O-(CH2)n-CO2H
CH
3
C(CH
2 -O-PEG-OH)3
CH
3
C[CH
2 -O-PEG-02C-(CH2)n-0-PEG-O(CH2)-CO2-]3} m
-H
2 0 The degree of polymerization is given by m, which refers to "matrix" and is intended to indicate that a crosslinked polymer has been formed as a solid aggregate. N is from about 1 to 10 and can be varied to control the rate of hydrolysis of the gel, usually by increasing N to decrease the rate of hydrolysis. It should be understood that the degree of polymerization by the formation of crosslinks is large and indeterminate. The PEG hydrogel that is formed is a visible and solid aggregate that swells in water in which, in theory, all available crosslinks are formed. However, it is not usually possible to determine the degree of crosslinking that has occurred.
The rate of release of drug molecules trapped within the matrix is controlled by controlling the hydrolytic breakdown rate of the gel. The hydrolytic breakdown rate of the gel can.be adjusted by controlling the degree of bonding of the PEGs that form the hydrogel matrix. A multiarmed PEG having 10 branches or arms will break down. and release drug molecules more slowly than a 3 armed PEG.
Substantially precise control of hydrolytic breakdown rate and drug release can be provided by varying the atoms near the hydrolytically unstable linkages. Typically, increasing the n value (the number of methylene groups) in the above structure decreases the hydrolysis rate of esters and increases the time required for the gel to degrade. If n in the above example is 1, then the ester linkages of the gel will hydrolyze with a half life of about 4 days at pH 7 and 37 0 C. If n is 2, then the half life of hydrolytic degradation of the ester linkages is about 43 days at pH 7 and 370C.
Phosphate esters, acetals, imines, and other hydrolytically unstable linkages can be similarly formed and the hydrolysis rate can be similarly controlled by controlling the number of methylene groups adjacent the hydrolytically unstable linkage and by controlling the degree of branching of the PEG.
The degradable hydrogels of this invention can also be made by a two-step process. In the first step, soluble, uncrosslinked PEGs are prepared that have hydrolytically unstable linkages in their backbones. In the second step, these PEGs with hydrolytically unstable linkages in their backbones are coupled together with other PEGs by hydrolytically stable linkages. For example, the following PEG has two hydrolytically unstable ester linkages in its backbone: NHS-OC-CH-O-PEG-O-CH-CO2-PEG-O-C-O-PEG-O-CH,-CO,-NHS The above PEG is' activated at each terminus with an N-hydroxylsuccinimide moiety (NHS) in which the active succinimidyl ester moiety is NHS-CO,- and is reactive with amino groups. When this PEG is coupled with a multiarmed PEG amine, a crosslinked network is produced that is held together by stable amide linkages that are formed from the reaction of the active esters with amine and by the hydrolytically unstable ester linkages already present in the backbone. As in the previous example, the degradation rate of the gel is controlled by varying the number of methylene groups adjacent to the ester linkage.
The two-step method described above for making the PEG hydrogels can be used to form the gel and to trap substances in situ, in living tissue, for injectable drug systems. A drug can be combined with one reactive PEG component of the hydrogel and injected along with another reactive PEG component that will form the gel. The drug is trapped within the matrix that is formed because of its proximity to the reactive system.
Thus, the invention provides, among other things, degradable PEG hydrogels having hydrolytically unstable linkages in which the rate of hydrolysis of the unstable linkages can be controlled. The PEG hydrogels of the invention can physically trap drugs, including proteins, enzymes, and a variety of other substances, in the absence of covalent linkages, for precisely controlled release in vivo. The degraded gel can be more readily cleared from the body than can gels that do not significantly degrade.
The foregoing and other objects, advantages, and features of the invention, and the manner in which the same are accomplished, will be more readily apparent upon consideration of the following detailed description of the invention taken in conjunction with the accompanying drawing, which illustrates an exemplary embodiment.
BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a schematic representation of a PEG hydrogel in which the PEGs have three branches or arms.
DETAILED DESCRIPTION Figure 1 illustrates a poly(ethylene glycol) (PEG) matrix held together by hydrolytically unstable or weak linkages W. The PEGs shown in Figure 1 have three branches or arms. The degree of branching can be varied in the hydrogels of the invention to control the physical strength and compressibility of the gels; in general the greater the degree of branching and the shorter the branches, the greater the strength (resistance to compression or stretching) of the gels.
Similarly, greater degrees of branching and shorter branches also give smaller pores and lower water content.
Degradable PEG hydrogels having hydrolytically unstable PEGs can be prepared in one step, as shown in the following general equation: Z-PEG-Z R(CH,-O-PEG-Y), (R[CH,-O-PEG-W-PEG-W-]p}m where m means "matrix" and indicates a degree of polymerization such that a crosslinked polymer, which is a solid aggregate is formed. m is large and indeterminate. p is 3 to 10 and refers to the degree of branching, which is the number of arms, of the reactant branched PEG, R(CH 2 -O-PEG-Y)p. The rate of hydrolysis of the PEG gel typically is lengthened by increasing p. R is a central branching moiety suitable for making multiarmed PEGs and includes moieties selected from the group consisting of glycerol, glycerol oligomers, pentaerythritol, sorbitol, trimethyolpropane, and di(trimethylolpropane). Z and Y are groups that react to form hydrolytically unstable linkages W. Examples of pairs of the groups Z and Y that can be reacted to form hydrolytically unstable linkages W include pairs selected from the group consisting of alcohol and carboxylic acid reacting to 0 form carboxylate esters, amine and aldehyde reacting to form imines, hydrazide CN and aldehyde reacting to form hydrazones, alcohol and phosphate reacting to form phosphate ester, aldehyde and alcohol reacting to form acetals, alcohols and formate reacting to form orthoesters.
It should be noted that the Z groups are shown on a linear PEG and the Y groups are shown on a branched PEG. However, the reaction will proceed and 00 oo the gel will be formed with the Y groups on the linear PEG and the Z groups on oo the branched PEG to form the same weak linkages W.
e A specific example of the one-step method for making a PEG hydrogel o 10 having hydrolytically unstable carboxylate ester linkages W formed by the cN reaction of PEG carboxylic acid and PEG hydroxyl groups Z and Y, respectively, is shown by the following equation: HO2C-(CH 2 )n-O-PEG-O-(CH 2 )n-CO 2 H+ R(CH 2 -O-PEG-OH)p {R[CH2-0-PEG-02C-(CH 2 )n-O-PEG-O(CH2)n-CO2-]p}m In the above equation, m, p, and R are as characterized above. n is from about 1 to 10, and can be varied to control the rate of hydrolysis of the gel.
Increasing n typically decreases the rate of hydrolysis.
Note that in this example the hydroxyl group is on the branched PEG while the carboxylic acid groups are on the linear PEG. Alternatively, the hydroxyl group could be on the linear PEG while the carboxylic acid could be on the branched PEG.
Degradable PEG hydrogels can also be prepared in two steps. In the first step a linear PEG is prepared having one or more hydrolytically unstable linkages W in its backbone. The linear PEG has the general formula U-PEG-W-PEG-U, in which U represents a reactive terminal moiety and W is the hydrolytically unstable linkage.
In the second step the PEG with the hydrolytically unstable linkages in its backbone is reacted with a second PEG. The second PEG is a branched PEG, as shown in the general formula R(CH2-O-PEG-V)p, in which V represents a reactive terminal moiety. P is 3 to and refers to the degree of branching, which is the number of arms, of the 11 0 reactant branched PEG, R(CH 2 -O-PEG-V)p. The rate of hydrolysis of the PEG N gel typically is lengthened by increasing p. R is a central branching moiety Ssuitable for making multiarmed PEGs and includes moieties selected from the group consisting of glycerol, glycerol oligomers, pentaerythritol, sorbitol, trimethyolpropane, and di(trimethylolpropane).
The functional groups U and V at the ends of the PEG polymer chains in 00 oo the first and second PEGs, respectively, react to form hydrolytically stable 00 crosslinks X, as shown by the following equation.
c-i U-PEG-W-PEG-U
R(CH
2 -O-PEG-V)p (N {R[CH2-O-PEG-X-PEG-W-PEG-X-]p}m Again, m means "matrix" and indicates a degree of polymerization such that a crosslinked polymer, which is a solid aggregate is formed. W is a hydrolytically unstable group including carboxylate esters, imines, hydrozones, phosphate esters, acetals and orthoesters. U and V are groups reactive toward each other, including active esters, -12which includes carbonate esters, reacting with amines, isocyanates reacting with alcohols, isocyanates reacting with amines, aldehydes reacting with amines and a reducing agent, epoxide reacting with amines, and sulfonate esters reacting with amines.
The hydrolytically stable linkages X that are formed by the reaction of U and V include amide from the reaction of active esters with amine, urethane from the reaction of isocyanate with alcohol, urea from the reaction of isocyanate with amine, amine from the reaction of aldehyde with amine and reducing agent, amine from the reaction of epoxide with amine, and sulfonamide from the reaction of sulfonate ester with amine.
A specific example of the two-step method is the preparation of degradable PEG hydrogels having hydrolytically unstable carboxylate ester linkages W and hydrolytically stable amide linkages X that are formed by the reaction of active esters U and amines V as shown in the following equation.
NHS-O0C-(CH,)n,-O-PEG-W-PEG-O-(CH, 2
)-CO
2 -NHS R(CH 2
-O-PEG-NH,),
R[CH,-O-PEG-NHCO- ,--PEG-W-PEG-O-(CH,) -CONH-]p} The symbols n, m, p, and R are as previously described. W is a hydrolytically unstable ester linkage according to the formula -0-(CH 2 )r-CO 2 in which r is from about 1 to The amino group V is on the branched PEG while the active esters U are on the linear PEG. It should be recognized that the two groups could be exchanged so that the amino group is presented on the linear PEG while the active ester is presented on the branched PEG.
In a second two-step method, a reactant linear PEG is prepared in a first step having hydrolytically unstable linkages W near the polymer O chain terminal groups in a second step the PEG having hydrolytically cN unstable linkages W near the polymer chain terminal groups is reacted with a branched PEG having a reactive moiety V to form hydrolytically stable crosslinks
X.
U-R'-W-PEG-W-R'-U R(CH 2 -O-PEG-V)p 00 00 {R[CH2-O-PEGPEG-X-R'-W-PEG-W-R'-X]p}m 00 M The symbols m, p, and R are as previously defined. R' is a small 0 10 hydrocarbon fragment having from about 1 to 10 carbons. W is a hydrolytically N unstable group including carboxylate esters, imines, hydrozones, phosphate esters, acetals and orthoesters as previously defined. U and V are groups reactive toward each other, including active esters, which includes carbonate esters, reacting with amines, isocyanates reacting with alcohols, isocyanates reacting with amines, aldehydes reacting with amines and a reducing agent, epoxides reacting with amines, and sulfonate esters reacting with amines.
The hydrolytically stable linkage formed by reaction of U and V is X. X includes amide from the reaction of active ester with amine, urethane from the reaction of carbonate ester with amine, urethane from the reaction of isocyanate with alcohol, urea from the reaction of isocyanate with amine, amine from the reaction of aldehyde with amine and reducing agent, amine from the reaction of epoxide with amine, and sulphonamide from the reaction of sulfonate ester with amine.
A specific example, which is shown in the following equation, is the formation of PEG hydrogels containing hydrolytically unstable carboxylate ester groups W and hydrolytically stable amides X formed by the reaction of active esters U and amines V, and in which the hydrolytically unstable carboxylate ester groups W have been separated from the U and or V groups by a small hydrocarbon fragment in the precursor linear
PEG.
NHS-0 2 C- (CH 2 i-0C- (CH 2 n-O-PEG-O- (CH 2
-CO
2
(CH
2 i-CO 2
-NHS
R(CH
2
-O-PEG-NH
2 p
{R[CH
2 -O-PEG-NHCO-(CH2) i-02C- (CH 2 n-O-PEG-O- (CH 2 n-CO 2
(CH
2 )n-CONH-] }m In the above equation, i is from about 1 to 10 and defines the length of the small.hydrocarbon fragment The symbols n, m, p and R are as previously defined. An amino group is shown on the branched PEG while the active esters are shown on the linear PEG. It should be recognized that the two groups could be exchanged so that the amino group is on the linear PEG and the active ester is on the branched
PEG.
The skilled artisan should recognize that when reference is made to a Z moiety reacting with a Y moiety or to a U moiety reacting with a V moiety, that additional reagents or steps may be employed according to commonly accepted chemical procedures and standards to achieve the desired linkage W or X as the case may be. There are many possible routes, too numerous to mention here, that could be taken and that should be readily apparent to the skilled artisan. For example, one of skill in the art can be expected to understand that when an alcohol and a carboxylic acid are reacted, the acid typically is converted to another form, the acid chloride, prior to reaction with alcohol. Several examples are demonstrated in the Examples below.
Hydrogels made from the crosslinked PEG polymeric structures of the invention can be used in drug delivery systems and for wound dressings. Wound dressings could be used internally to provide dressings that degrade within the body over time. The hydrogels of the invention could be usefully applied in drug delivery systems to burns to apply therapeutic agents to burns. Drug delivery systems can be prepared in which the rate of hydrolysis of the hydrogel is controlled to provide controlled release of drug components. By "drug" is meant any substance intended for the diagnosis, cure, mitigation, treatment, or prevention of disease in humans-and other animals, or to otherwise enhance physical or mental well being.
The invention -could- be used--for delivery of biologically active substances generally that have some activity or function in a living organism or in a substance taken from a living organism.
The terms "group," "functional group," "moiety," "active moiety," "reactive site," and "radical" are all somewhat synonymous in the chemical arts and are used in the art and herein to refer to distinct, definable portions or units of a molecule and to units that perform some function or activity and are reactive with other molecules or portions of molecules.
The term "linkage" is used to refer to groups that normally are formed as the result of a chemical reaction and typically are covalent linkages.
Hydrolytically stable linkages means that the linkages are stable in water and do not react with water at useful pHs for an extended period of time, potentially indefinitely. Hydrolytically unstable linkages are those that react with water, typically causing degradation of a hydrogel and release of substances trapped within the matrix. The linkage is said to be subject to hydrolysis and to be hydrolyzable. The time it takes to degrade the crosslinked polymeric structure is referred to as the rate of hydrolysis and is usually measured in terms of its half life.
The skilled artisan should recognize that when reference is made to a Z moiety reacting with a Y -16moiety or to a U moiety reacting with a V moiety, that additional reagents or steps may be employed according to commonly accepted chemical procedures and standards to achieve the desired linkage W or X as the case may be. There are many possible routes, too numerous to mention here, that could be taken and that should be readily apparent to the skilled artisan. For example, one of skill in the art can be expected to understand that when an alcohol and a carboxylic acid are reacted, the acid typically is converted to another form, the acid chloride, prior to reaction with alcohol. Several examples are demonstrated in the Examples below.
The following examples show the synthesis of various examples of the invention.
EXAMPLES
EXAMPLE 1 Example 1 shows preparation of a degradable PEG hydrogel having a hydrolytically unstable ester linkage. In an aluminum pan of 1 inch diameter, difunctional PEG 2000 acid (600 mg, 0.6 mmole end groups, available from Shearwater Polymers in Huntsville, Alabama) and one equivalent of 8-arm PEG 10,000 (750 mg, Shearwater Polymers) were mixed with mg stannous 2-ethylhexanoate (Sigma Chemical) and melted. PEG acids used included PEG carboxymethyl acid
(-PEG-OCH
2 COOH), PEG propionic acid (-PEG-O-CH 2
CH
2
COOH),
and PEG succinic acid (-PEG-OOCCH 2
CH
2 COOH). After a thin film of the melt covered the pan surface uniformly, the pan was heated under vacuum at 130 0 C and 100 millitorr for 6-24 hours. A firm, transparent gel formed. After cooling in a N 2 stream, the gel became translucent and was cut into thin disks and purified by the following procedures.
The crude gels were swollen in glacial acetic acid and washed three times with this solvent during a 2-3 days period. For hydrogels with a low swelling degree, swelling was conducted in dioxane before the -17wash with glacial acetic acid to avoid breaking of highly crosslinked gels. After washing, the gels were dried under vacuum. The tin content of the gel was determined by inductively coupled plasma spectroscopy to be less than 60 ppm.
Example 2 Example 2 shows preparation of a degradable PEG hydrogel having a hydrolytically unstable imine linkage. In a test tube, difunctional PEG propionic aldehyde 3400 (100 mg, 58.8 Amole, Shearwater Polymers) and 8-arm PEG amine 10,000 (74 mg, 58.8 Amole) were dissolved in 1,4-dioxane (Aldrich Chemical). The test tube was heated on an oil bath at 70 0 C for about two hours. The gel was then dried under reduced pressure at room temperature.
The PEG aldehydes used included PEG propionaldehyde
(-PEG-OCH
2
CH
2 CHO), PEG acetaldehyde
PEG-OCH
2 CHO)., and PEG benzaldehyde (-PEG-O-C 6
H
4
-CHO).
Examples 3 and 4, below, show preparation of PEG derivatives having hydrolytically unstable linkages for use in preparing the degradable hydrogel of the invention.
Example 3 Example 3 shows synthesis of.PEG derivatives having hydrolytically unstable backbone linkages and NHS active carbonates at each terminus thereof. The PEG derivative can be represented as NHS-OOCO-PEG-W- PEG-OCOO-NHS where W represents the hydrolytically unstable linkage. In a 100 ml round-bottom flask, benzyloxy-PEG carboxymethyl acid 3400 (3.4 g, Immol, Shearwater Polymers) in toluene was azeotropically distilled for two hours and then cooled to room temperature. A solution of thionyl chloride (2M, 4 ml, 8 mmole, Aldrich) in methylene chloride was injected and the mixture was stirred under N 2 overnight. The solvent was condensed by rotary evaporation and the syrup was dried in vacuo for about four hours over P 2 zO -18powder. To the residue was added anhydrous methylene chloride (5 ml) and azeotropically dried benzyloxy-PEG 3400 (2.55 g, 0.75 mmol) in toluene (20 ml). After the benzyloxy-PEG acyl chloride was dissolved, freshly distilled triethylamine (0.6 ml) was added. The mixture was stirred overnight, the triethylamine salt filtered off, and the product collected by precipitation with ethyl ether. It was further purified by dissolving in water and extracting with methylene chloride. The organic phase was dried over anhydrous sodium sulfate, condensed under vacuum, and precipitated into ethyl ether. The precipitate was dried in vacuo. HPLC (GPC) of the product showed that 100% of benzyloxy-PEG had been converted into the PEG ester and about 15% wt% benzyloxy-PEG acid remained.
The mixture was chromatographically purified on an ion-exchange column (DEAE sepharose fast flow, Pharmacia) to remove the benzyloxy-PEG acid. 100% pure a-benzyloxy--benzyloxy PEG ester 6800 was obtained.
Yield: 4.1 gram A solution of a-benzyloxy-T-benzyloxy
PEG
ester 6800 (2 g, 0.59 mmole) in 1,4-dioxane (20 ml) was hydrogenolyzed with H 2 (2 atm pressure) and Pd/C (1 g, Pd) overnight. The catalyst was removed by filtration and the product precipitated into ethyl ether after most of the solvent was removed on a rotary evaporator. a-hydroxy-a-hydroxy PEG ester 6800 was collected by filtration and dried in vacuo. Yield: gram a-hydroxy-m-hydroxy PEG ester 6800 (1.5 g, 0.44 mmole end group) was azeotropically dried with 100 ml acetonitrile and cooled to room temperature. To this solution was added disuccimidyl carbonate (DSC) (0.88 mmole, Fluka) and pyridine (0.1 ml), and the solution was stirred at room temperature overnight.
The solvent was removed under vacuum and the syrup was dried in vacuo. The product was dissolved in 35 ml of -19dry methylene chloride, the insoluble solid was removed by filtration, and the filtrate washed with pH sodium chloride saturated acetate buffer. The organic phase was dried over anhydrous sodium sulfate, condensed under vacuum, and precipitated into ethyl ether. The precipitate was dried over P 2 0 5 in vacuo.
Yield: 1.4 g NMR (DMSO-d 6 product from benzyloxy-PEG propionic acid: 6 3.5 (br m, PEG), 2.55
-OCH
2
CH
2 COOPEG-), 4.13 -PEG-COOCH 2 CHO-), 4.45
-PEGOCH
2 CH20CO-NHS), 2.80 NHS, 4H); product from benzyloxy-PEG carboxymethyl acid: 6 3.5 (br m, PEG), 4.14 -OCHCOOPEG-), 4.18 -OCH 2
COOCHCH
2 4.45 -PEGO-CH 2
CH
2 OCONHS), 2.81 NHS, 4H].
Example 4 Example 4 shows synthesis of PEG derivatives having hydrolytically unstable backbone linkages and terminal NHS active esters. The PEG derivative can be represented by the formula NHS-OOC-(CH 2
),-O-PEG-W-PEG-O-
(CH
2 )n-COONHS where W is a hydrolytically unstable linkage. In a 100 ml round-bottom.flask, a-hydroxy-PEG acid 2000 (4 g, 2 mmol, Shearwater Polymers) and difunctional PEG propionic acid 2000 (4 g, 2 mmole, Shearwater Polymers) were azeotropically distilled with ml toluene under N 2 After two hours, the solution was cooled to room temperature and stannous 2ethylhexanoate (200 mg, Sigma Chemical) was added. The solution was then refluxed under N 2 for 24 hours. The solvent was then condensed under vacuum and the syrup precipitated into 100 ml of ether. The product was collected by filtration, dried under vacuum, and dissolved in a sodium acetate buffer solution at pH The slightly milky solution was centrifuged and the upper clear solution was extracted three times with methylene chloride. The organic phase was dried over anhydrous sodium sulfate, filtered, condensed under vacuum, and precipitated into ether. The product was collected by filtration and dried under vacuum. Yield 7 g HPLC: 70% product, 15% di-acid reactant and monoacid. The mixture was further purified by ion exchange chromatography and gel permeation chromatography. 1H NMR (DMSO-d 6 product from PEG carboxymethyl acid: 6 3.5 (br m, PEG), 4.15 OCH2COOCH 2 4.18 -OCH 2 COOCH2CH 2 product from PEG propionic acid: 6 3.5 (br m, PEG), 2.58
OCH
2
CH
2 COOCH2-) 4.13 -OCH 2
CH
2 COOC2CH 2 In a round-bottom flask, the difunctional acid having weak linkages (obtained from previous step) (2 g. approx. 1 mmole end group) and Nhydroxysuccinimide (NHS) (126 mg, 1.05 mmole) were dissolved in 50 ml of dry methylene chloride. To this solution was added dicyclohexylcarbodiimide (240 mg, 1.15 mmole) in 5 ml dry methylene chloride. The mixture was stirred under N 2 overnight. The solvent was condensed and the syrup was redissolved in 15 ml of anhydrous toluene. The insoluble salt was removed by filtration and the filtrate was precipitated into 200 ml of dry ethyl ether. The precipitate was collected by filtration and dried in vacuo. Yield 1.88 g 1H NMR(DMSO-d) 6 3.5 (br m, PEG), 2.8 NHS, 4H), 4.6 -PEG-O-CH2-COONHS) or 2.85 -PEG-0-CH 2
CH
2
COONHS).
Example Example 5 shows preparation of a degradable PEG hydrogel from branched PEG amine and PEG derivatives made in accordance with Example 3 in which the PEG derivatives have hydrolytically unstable backbone linkages and terminal NHS active carbonates, which can be represented as NHS-OOCO-PEG-W-PEG-OCOO- NHS. In a test tube, 100 mg (4.7 Amole) of difunctional PEG active carbonate 6800 (NHS-OOCO-PEG-W- PEG-OCOONHS, prepared in Example 3) was dissolved in 0.75 ml of water, and a buffered solution (0.1M phosphate, pH 7) of 0.15 ml 8-arm-PEG-amine 10,000 (250 mg/ml) was added. After rapid shaking, it was allowed -21to sit and a gel formed in a few minutes. A suitable buffer pH range was found to be 5.5 to 8.
Example 6 Example 6 shows preparation of degradable PEG hydrogels from branched PEG amine and PEG derivatives made in accordance with Example 4 in which the PEG derivatives have hydrolytically unstable backbone linkages and terminal NHS active carbonates that can be represented as NHS-OOC-(CH 2 )n-O-PEG-W-PEG-O-(CH,)n-COO- NHS. 100 mg (approx. 50 .imole) difunctional PEG active ester (NHS-OOC-(CH 2 )n-O-PEG-W-PEG-O-
(CH
2
)-COO-NHS,
prepared in Example 4) was dissolved in 0.75 ml of water, and a buffered solution (0.1M phosphate, pH 7) of 0.25 ml 8-arm-PEG-amine 10,000 (250 .mg/ml) was added. After rapid shaking, it was allowed to sit and a gel formed in a few minutes. A suitable buffer pH range was found to be 5.5 to 8.
Example 7 Example shows the synthesis of difunctional PEG-hydroxybutyric acid (HBA), which can be represented as HOOC-CH 2
-CH(CH
3
)-OOC-(CH
2 )n-O-PEG-0-(CH 2 )n-
COOCH(CH
3
)CH
2 -COOH for use in preparing the reactive PEGs of Example 8. PEG acid 2000 (2.0 g, 1 mmole, carboxymethyl acid (CM) or propionic acid was azeotropically dried with 60 ml toluene under N 2 After two hours, the solution was cooled to room temperature and thionyl chloride (3 ml, 6 mmole, in CH 2 C1 2 was added. The mixture was then stirred at room temperature overnight and the solution condensed by rotary evaporation. The residue was dried in vacuo for about four hours with P 2 0O powder. 3-hydroxybutyric acid (0.30 g, 2.7mmole) was azeotropically dried with ml 1,4-dioxane until approximately 20 ml of solution remained. The solution was then cooled to room temperature under N 2 and to it was added dried PEG acyl chloride from the above step. After the PEG was dissolved, 0.6 ml dry triethylamine was injected into -22the system and the reaction mixture was stirred overnight. The salt was filtered from the solution, the solvent condensed on a rotary evaporator, and the syrup was dried in vacuo. The crude product was dissolved in 100 ml distilled water and the pH adjusted to 3.0. The product was extracted three times with a total of 80 ml of methylene chloride. The organic phase was dried over anhydrous sodium sulfate, filtered, condensed under vacuum, and precipitated into 100 ml of ethyl ether. The product was collected by filtration and dried in vacuo. Yield 1.84 g 1H NMR (DMSO-d) 6 3.5 (br m, PEG), 2.54 (d,
PEGCOOCH(CH
3
C&
2 COOH), 5.1 PEGCOOCH(CH 3
CH
2
COOH),
1.21 PEG-COOCH(CH 3 )CHCOOH), 2.54 PEGOCH 2
CH
2
COO
4.05 PEGOCH 2 COO Example 8 Example 8 shows.the synthesis of difunctional PEG-HBA-NHS double ester, which can be represented as NHS-OOC-CH,-CH (CH 3 )-OOC- (CH, 2 -O-PEG-O- (CH 2 )n-
COOCH(CH
3
)CH
2 -COONHS, for use in preparing PEG hydrogels of the invention. PEG-3-butyric acid (Ig, approx. mmole, prepared in example 7) and 64 mg Nhydroxysuccinimide (NHS) (0.53 mmole) were dissolved in ml of dry methylene chloride, followed by addition of dicyclohexylcarbodiimide (DCC, 126 mg, 0.6 mmole) in ml dry methylene chloride. The solution was stirred under nitrogen overnight and the solvent removed by rotary evaporation. The residue was stirred with 10 ml dry toluene at 45 0 C and the insoluble solid was removed by filtration. The product was precipitated into 100 ml of dry ethyl ether and the precipitate was collected by filtration and dried in vacuo. Yield 0.94 g 1 H NMR(DMSO-d 6 6 3.5 (br m, PEG), 3.0-3.2
COOCH(CH
3
)CH
2 COONHS), 5.26 -COOCH(CH 3
)CH
2 COONHS), 1.3
-CO-OCH(CH
3
)CH
2 COONHS), 2.54 -PEGOCHCH2COO- 4.1 -PEGOCH2COO-(CM)).
Example 9 23 0 Example 9 shows the preparation of a degradable PEG hydrogel from N branched PEG amine and the PEG-HBA-NHS double ester of Example 8, which Scan be represented as NHS-OOC-CH 2 -CH(CH3)-OOC-(CH 2 )n-O-PEG-O-(CH 2 )n- C COOCH(CH 3 )CH2-COONHS. PEG-HBA-NHS double ester 2000 (100 mg, approx. 0.1 mmole, Example 8) was dissolved in 0.5 ml of water and a buffered solution of 8-arm-PEG-amine 10,000 (0.5 ml, 250 mg/ml) was added. After rapid oo shaking, it was allowed to sit and a gel formed in a few minutes. A suitable buffer 00 pH range was found to be 5.5 to 8.
n The invention has been described in particular exemplified embodiments.
However, the foregoing description is not intended to limit the invention to the cN exemplified embodiments, and the skilled artisan should recognize that variations can be made within the scope and spirit of the invention as described in the foregoing specification.
Comprises/comprising and grammatical variations thereof when used in this specification are to be taken to specify the presence of stated features, integers, steps or components or groups thereof, but do not preclude the presence or addition of one or more other features, integers, steps, components or groups thereof.
Claims (19)
1. A crosslinked polymeric structure comprising poly(ethyleneglycol) (PEG) Spolymers in the absence of non-PEG polymer, said PEG polymers crosslinked through groups which are reactive toward each other, and said PEG polymers having a central branching moiety and at least some hydrolytically unstable 00 linkages between said PEG polymers, said hydrolytically unstable linkages being M0 selected from the group consisting of carboxylate esters and phosphate esters, e imines, hydrazones, acetals and orthoesters, wherein the carboxylate ester is a S monomeric ester according to the formula -O-(CH 2 )r-CO 2 wherein r is from 1 to 10
2. The crosslinked polymeric structure of Claim 1 wherein said hydrolytically unstable linkages are sufficient to cause said crosslinked polymeric structure to degrade by hydrolysis.
3. The crosslinked polymeric structure of Claim 1 wherein said structure forms a PEG hydrogel that is subject to hydrolysis.
4. The crosslinked polymeric structure of Claim 3 wherein the PEG hydrogel formed therefrom has a rate of hydrolysis that is determined at least in part by the structure of said linkages between said PEG polymers.
The crosslinked polymeric structure of Claim 4 wherein said linkages comprise one or more methylene groups sufficient to determine at least in part said rate of hydrolysis of said hydrolytically unstable linkages.
6. The crosslinked polymeric structure of Claim 5 wherein said hydrolysis rate is decreased as the number of said methylene groups is increased.
7. The crosslinked polymeric structure of Claim 1 wherein said hydrolytically unstable linkages comprise linkages selected from the group consisting of carboxylate esters and phosphate esters. O
8. The crosslinked polymeric structure of Claim 1 wherein said structure also N comprises hydrolytically stable linkages that do not degrade, which hydrolytically Sstable linkages comprise linkages selected from the group consisting of amides, C urethanes, ureas, amines, and sulfonamides.
9. The crosslinked polymeric structure of Claim 1 having a Formula selected 00 from the group consisting of: 00 00 C a {R[CH2-O-PEG-X-PEG-W-PEG-X-]p}m {R[CH2-O-PEG-X-R'-W-PEG-W-R'-X-] wherein m means "matrix" and indicates that the crosslinked structure is a solid aggregate; p is from 3 to 10 and indicates the number of arms on the polymers forming said crosslinked structure; R is a moiety selected from the group consisting of glycerol, glycerol oligomers, pentaerythritol, sorbitol, trimethylolpropane, and di(trimethylolpropane); R' is a hydrocarbon fragment having from 1 to 10 carbons; W is a hydrolytically unstable linkage comprising, linkages selected from the group consisting of carboxylate esters and phosphate esters, imines, hydrazones, acetals, orthoesters, wherein the carboxylate ester is an ester according to the formula -O-(CH 2 )r-CO 2 wherein r is from 1 to 10; and X is a hydrolytically stable linkage comprising linkages selected from the group consisting of amides, urethanes, ureas, amines, and sulfonamides.
The crosslinked polymeric structure of Claim 1 having the formula: {R[CH2-0-PEG-02C-(CH2)n-O-PEG-O(CH2)n-CO2-]p}m wherein m means "matrix" and indicates that the crosslinked structure is a solid aggregate; p is from 3 to 10 and indicates the number of arms on the polymers forming said crosslinked structure, R is a moiety selected from the group consisting of glycerol, glycerol oligomers, pentaerythritol, sorbitol, trimethylolpropane, and di(trimethylolpropane); and wherein n is from 1 to O
11. The crosslinked polymeric structure of Claim 1 having the formula: {R[CH2-O-PEG-02C-(CH2)n-O-PEG-O(CH 2 )n-CO 2 -]p}m wherein m means "matrix" and indicates that the crosslinked structure is a solid aggregate, and wherein n is from 1 to 10, and wherein when n equals 2, then the oo ester linkages have a hydrolysis half life of about 4 days at pH7 and 37 degrees oo Centigrade, and wherein when n equals 3, then the ester linkages have a e hydrolysis half life of about 43 days at pH7 and 37 degrees Centigrade. 0 c 10
12. A drug delivery system comprising the crosslinked polymeric structure of any one of Claims 1 to 11.
13. The crosslinked polymeric structure according to any one of claims 1 to 11 for use as a medicament.
14. The use of the crosslinked polymeric structure according to any one of claims 1 to 11 for the manufacture of a medicament.
A kit comprising separate units wherein a first unit contains at least one biologically active substance together with either a linear PEG or a branched PEG and a second unit contains the PEG which does not contain the at least one biologically active substance, wherein upon combining the contents of the first and second unit the linear and branched PEGs react to form a degradable hydrogel matrix in which the biologically active substance is trapped, and wherein upon hydrolysis the hydrogel degrades and releases the biologically active substance.
16. A method for making a crosslinked polymeric structure comprising reacting a linear poly(ethylene glycol) (PEG) polymer of the formula Z-PEG-Z with a branched PEG polymer of the formula R(CH2-O-PEG-Y)p to provide a crosslinked structure of the formula {R[CH2-O-PEG-W-PEG-]p}m, wherein m means "matrix" and indicates that the crosslinked structure is a solid aggregate; p is from 3 to O and indicates the number of arms on the polymers forming said crosslinked cN structure; R is a central branching moiety suitable for making multiarmed PEGs, and wherein Z reacts with Y to form the hydrolytically unstable group W, and Z and Y are selected from the group consisting of alcohols, carboxylic acids, amines, aldehydes, hydrazides, phosphate, formates, and wherein W is selected from the group consisting of carboxylate esters, phosphate esters, imines, 00 hydrazones, acetals and orthoesters. 00 (n
17. A method for making a crosslinked polymeric structure comprising reacting o a linear poly(ethylene glycol) (PEG) with a branched PEG polymer according to 10 the following equation: U-PEG-W-PEG-U R(CH 2 -O-PEG-V)p o wherein W is selected from the group consisting of esters, imines, hydrazones, acetals and orthoesters, wherein U reacts with V to form X, and U and V are selected from the group consisting of active esters, amine, isocyanate, aldehyde, epoxide, and sulfonate ester; wherein X is selected from the group consisting of amides, urethanes, ureas, amines, and sulfonamides; and wherein m means "matrix" and indicates that the crosslinked structure is a solid aggregate; p is from 3 to 10 and indicates the number of arms on the polymers forming said crosslinked structure; and R is a central branching moiety suitable for making multiarmed PEGs.
18. A method for making a crosslinked polymeric structure comprising reacting a linear poly(ethylene glycol) (PEG) with a branched PEG polymer according to the following equation: U-R'-W-PEG-W-R'-U R(CH 2 -O-PEG-V) O wherein R' is a hydrocarbon fragment having from 1 to 10 carbons; wherein W is N selected from the group consisting of esters, imines, hydrazones, acetals and orthoesters; wherein U reacts with V to form X, and U and V are selected from the group consisting of active esters, amine, isocyanate, aldehyde, epoxide, and sulfonate ester; wherein X is selected from the group consisting of amides, urethanes, ureas, amines, and sulfonamides, and wherein m means "matrix" and 00 oo indicates that the crosslinked structure is a solid aggregate; p is from 3 to 10 and oo indicates the number of arms on the polymers forming said crosslinked structure; m and R is a central branching moiety suitable for making multiarmed PEGs. 0 c 10
19. A crosslinked polymeric structure substantially as hereinbefore described with reference to the examples and Figure 1. A method for making a crosslinked polymeric structure substantially as hereinbefore described with reference to the examples. DATED this 14th day of February 2005 DEBIO RECHERCHE PHARMACEUTIQUE SA WATERMARK PATENT TRADE MARK ATTORNEYS 290 BURWOOD ROAD HAWTHORN VICTORIA 3122 AUSTRALIA P17134AU01 KJS/JPFNRH
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2002328388A AU2002328388B2 (en) | 1997-09-12 | 2002-12-17 | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08928049 | 1997-09-12 | ||
| AU60293/98A AU6029398A (en) | 1997-09-12 | 1998-01-23 | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
| AU2002328388A AU2002328388B2 (en) | 1997-09-12 | 2002-12-17 | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU60293/98A Division AU6029398A (en) | 1997-09-12 | 1998-01-23 | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002328388A1 AU2002328388A1 (en) | 2003-04-10 |
| AU2002328388B2 true AU2002328388B2 (en) | 2005-04-14 |
Family
ID=39272651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002328388A Ceased AU2002328388B2 (en) | 1997-09-12 | 2002-12-17 | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2002328388B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118420916A (en) * | 2024-07-03 | 2024-08-02 | 浙江巴泰医疗科技有限公司 | Preformed blood sealing plug and preparation method thereof |
-
2002
- 2002-12-17 AU AU2002328388A patent/AU2002328388B2/en not_active Ceased
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118420916A (en) * | 2024-07-03 | 2024-08-02 | 浙江巴泰医疗科技有限公司 | Preformed blood sealing plug and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1019446B1 (en) | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor | |
| US6558658B2 (en) | Delivery of poly (ethylene glycol)-modified molecules from degradable hydrogels | |
| US7214388B2 (en) | Degradable heterobifunctional poly(ethylene glycol) acrylates | |
| AU2002328388B2 (en) | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |